Clinical Trial Detail

NCT ID NCT03329950
Title A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Celldex Therapeutics
Indications

ovarian cancer

liver cancer

cholangiocarcinoma

melanoma

transitional cell carcinoma

esophageal cancer

breast cancer

fallopian tube cancer

colorectal cancer

pancreatic adenocarcinoma

non-small cell lung carcinoma

stomach cancer

renal cell carcinoma

peritoneum cancer

head and neck cancer

Therapies

CDX-1140 + CDX-301

CDX-1140

Age Groups: senior adult

No variant requirements are available.